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Abstract
Background
HIV-2 is primarily endemic in West Africa and India, however, in time of global migration, a
possible HIV-2 infection or co-infection with HIV-1 should be recognized right at the time of
HIV diagnosis, in order to enable optimized antiretroviral treatment. Laboratory HIV testing
consists of a combined HIV1/2/O antibody + antigen screening test and subsequent confir-
mation and type differentiation by a serological test formatted as a multi-line or multi-spot
assay. CDC has proposed a revised alternative HIV diagnostic strategy which, in case of a
reactive result in a combined HIV1/2/O antibody + antigen screening test, comprises an
HIV-1 nucleic acid test (NAT) for HIV confirmation instead of an antibody differentiation
immunoassay (ADI). Only a negative NAT must be further investigated by an ADI, thus sav-
ing expenses for ADI in most instances. We have investigated this alternative strategy with
respect to its recognition of dual HIV-1 and HIV-2 infection.
Methods and Results
Anonymized data of HIV notifications of patients newly diagnosed with HIV in Switzerland
between 2007 and 2014 were analysed retrospectively. In a total of 4'679 notifications, we
found 35 HIV-2 infections, 9 (25.7%) of which were dually infected with HIV-1. In 7 of the 9
dual HIV-1 and HIV-2 infections, HIV-1 RNA testing at the time of HIV diagnosis was posi-
tive with concentrations from 102 to 94'300 copies/mL plasma. HIV-1 RNA data were not
available for the other two cases.
Conclusions
The alternative CDC strategy would have missed the concomitant HIV-2 infection in at least
7, but probably even more, of the 9 dually infected patients, as the detectable HIV-1 RNA
would have precluded a supplemental ADI. Early ADI is mandatory for diagnosis of dual
HIV-1/HIV-2 infection and guidance of appropriate therapy.
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Introduction
Accurate laboratory diagnosis of HIV is essential for patient management and treatment. The
current HIV diagnostic algorithm presented by the U.S. Centers for Disease Control and Pre-
vention (CDC) in June 2014 consists of a combined screening immunoassay, which detects
both p24 antigen and HIV antibodies, and subsequent confirmation and type differentiation by
a serological test formatted as a multi-line or multi-spot assay [1]. If this HIV-1/HIV-2 antibody
differentiation immunoassay (ADI) is nonreactive or indeterminate, an HIV-1 nucleic acid test
(NAT) is recommended [1]. An alternative testing algorithm using HIV-1 NAT as the confir-
matory test after a reactive screening assay instead of an ADI was also proposed [1]. In this
strategy, only a negative HIV-1 NAT result would be followed by an ADI, thus saving expenses
for ADI in most instances. This alternative testing algorithm was evaluated previously and iden-
tified a higher proportion of HIV infections than did ADI-based confirmation; however, it does
not allow for differentiation of acute from established HIV infection [2]. A further confirmatory
test was recommended to resolve discrepancies and avoid incorrect diagnoses [1, 2].
Based on a well-documented case of dual HIV-1 and HIV-2 infection where HIV-2 would
have been missed when following the alternative HIV testing algorithm we investigated how
many such dual infections would have been missed in recent years.
Material and Methods
Data origin and ethics statement
In Switzerland, anonymized HIV notifications for patients newly diagnosed with HIV infection
were reported to the Swiss Federal Office of Public Health (SFOPH) since 2007. There were
two types of notifications for each patient: (i) a laboratory notification with the diagnostic test
data sent in by one of the 11 regional HIV notification labs in Switzerland or the Swiss National
Center for Retroviruses of Switzerland, and (ii) a supplemental clinical notification forwarded
by the patient’s attending physician, with epidemiologic and clinical information relevant in
the context of HIV infection [3]. No informed consent was required, since both types of anony-
mous notifications are imposed by Swiss federal law. Notifications, which include the results of
all HIV laboratory tests performed at the time of HIV diagnosis were available since September
2007 [3]. We used these data for a search for dually infected patients. All data in this study
were contained in anonymized, legally mandatory HIV notifications to the SFOPH.
Laboratory testing methods
For confirmation of HIV infection and differentiation between HIV-1 and HIV-2, the line
immunoassay, INNO-LIA HIV I/II Score (Fujirebio, Ghent, Belgium) (Inno-Lia), had been
used in all patients at time of diagnosis. HIV-1 viral RNA plasma load had been measured by
the Cobas AmpliPrep/-Taqman HIV-1 version 2.0 (Roche Diagnostics, Rotkreuz, Switzerland)
with a detection limit of 20 copies/mL. HIV-2 RNA plasma load was assessed by a specific
HIV-2 RT-PCR with a detection limit of 100 copies/mL [4]. An ultra-sensitive high input assay
(Mega) PCR for verification of dual HIV-1/HIV-2 infection was performed with DNA
extracted from peripheral blood mononuclear cells (PBMC) as described [5].
Results
Case presentation of a HIV-1 and HIV-2 dually infected patient
In April 2012, a 27-year-old man (patient 1) originating from Guinea Bissau presented to a
hospital in Switzerland with fever and multiple lymphadenopathy. A fourth-generation
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HIV-1/2 antibody/antigen combination EIA screening test was reactive. Testing for p24 anti-
gen alone was negative. For confirmation of HIV infection and differentiation between HIV-1
and HIV-2, the Inno-Lia immunoassay revealed a band pattern indicating HIV-1 and HIV-2
co-infection (Fig 1). The plasma HIV-1 RNA load was high with 88’000 copies/mL. The base-
line CD4+ T cell count was 48 cells/μL (CD4 percentage, 5.5%). The HIV-2 RNA plasma load
was negative. Mega-PCR detected HIV-2 proviral DNA in PBMC of a second sample, thus
confirming a dual infection with HIV-1 and HIV-2. Genetic drug resistance testing of HIV-1
revealed HIV-1 of the recombinant clade CRF02_AG, and showed no mutations in the reverse
transcriptase region of the pol gene and only one mutation in the protease region, 20I, poten-
tially conferring low-level resistance to protease inhibitors (PI). After two weeks on antiretrovi-
ral treatment, the HIV-1 RNA in plasma had decreased to 5'251 copies/mL. The patient then
returned to his original country, and no follow-up samples were available.
Frequency of HIV-1 and HIV-2 dual infections in Switzerland
Among 4'679 notifications received between Sept 2007 and Dec 2014, 4'644 (99.3%) patients
were infected with HIV-1 and 35 patients (0.7%) were infected with HIV-2, respectively.
Including patient 1, a dual infection with HIV-1 and HIV-2 was suspected in 9 out of 35
patients (25.7%), based on serological data as shown by Inno-Lia (Table 1). Seven of these 9
patients had a detectable or high concentration of HIV-1 RNA in plasma, while the remaining
two had not been tested. Where tested, HIV-2 RNA was undetectable or only weakly positive
(Table 1).
Discussion
HIV-2 is most prevalent in West Africa and India, however, there are reports of HIV-2 in
Europe and the United States due to migration [6–8]. Switzerland or Austria are low-endemic
countries; notably, some of the HIV-2 infections are dual infections with HIV-1 [3, 9, 10]. Our
retrospective analysis of all HIV notifications for patients newly diagnosed with HIV infection
Fig 1. Line immunoassay of patient 1 showing seropositivity for both HIV-1 and HIV-2. Patient sample: specific HIV-1 envelope
antibodies (sgp120 and gp41) and specific HIV-2 envelope antibodies (gp36 and sgp105) are present. Positive and negative strip controls
are shown.
doi:10.1371/journal.pone.0157690.g001
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from Sept 2007 to Dec 2014 shows that a quarter of all patients with HIV-2 infection were
additionally infected with HIV-1. Moreover, most of the HIV-1 plus HIV-2 infections dis-
played rather high HIV-1 viral loads right at the time of HIV diagnosis (ranging from 102 to
94'300 copies/mL plasma). By applying the alternative HIV diagnostic algorithm presented
from CDC [1], which requires an ADI only in case of undetectable HIV-1 RNA in plasma, at
least 7 (20%) out of 35 HIV-2 infections would have been missed.
Previous observations have suggested that HIV-2 may exert a protective effect against HIV-
1 and it was thought that there is no simultaneous virus replication in dually infected patients
[11]. A review of the literature shows, however, that the combination of a high HIV-1 plasma
load with a low or undetectable HIV-2 plasma load, as we have observed in most of our dual
infections, is not rare [12]. Andersson et al. showed a significantly lower viral load set-point for
HIV-2 than for HIV-1 in a number of patients [13]. Moreover, with regard to the alleged pro-
tective effect of HIV-2, a higher risk for acquiring HIV-1 was observed for HIV-2 infected indi-
viduals [14]. Schutten et al. described two patients with dual HIV-1 and HIV-2 infections, who
displayed active replication of both viruses and had a clinical failure after ART against HIV-1
[15].
Early identification of HIV-2 is critical for patient management as all viruses of this type are
naturally resistant to the entire class of non-nucleoside reverse transcriptase inhibitors. More-
over, mutations conferring reduced susceptibility of HIV-2 to PIs were detected in dually
infected patients, leading to HIV-2 viral plasma rebounds or persisting plasma viral loads
[16, 17].
Verification of a serologically suspected HIV-2 infection still is challenging since current
commercial methods do not allow for detection of HIV-2 RNA loads in plasma samples, and
proper quantification of HIV-2 in plasma is complicated by limited HIV-2 standards and the
genetic diversity of specific HIV-2 strains [4]. Moreover, as many HIV-2 infected patients are
asymptomatic and have an undetectable or significantly lower HIV-2 RNA load in plasma
Table 1. Diagnostic results of patients with dual HIV-1/HIV-2 infection (n = 9).
Patient HIV line immunoassay (reactivity) HIV-1 RNA
[copies/ml]
HIV-2 RNA HIV-2 DNA high
input
1 HIV-2: sgp36 3+, sgp105 3+ HIV-1: sgp120 3+, gp41 3+, p31 3+, p24 3+,
p17 3+
88’000 undetected positive
2 HIV-2: sgp36 3+, sgp105 2+ HIV-1: sgp120 3+, gp41 3+, p31 2+, p24 4+,
p17 4+
94’300 undetected nda
3 HIV-2: sgp36 4+, sgp105 4+ HIV-1: sgp120 2+, gp41 3+, p31 3+, p24 3+,
p17 3+
3'690 weak-
positive
nd
4 HIV-2: sgp36 3+, sgp105 3+ HIV-1: sgp120 3+, gp41 3+, p31 3+, p24 3+,
p17 3+
21’000 undetected nd
5 HIV-2: sgp36 3+, sgp105 3+ HIV-1: sgp120 3+, gp41 3+, p31 3+, p24 3+,
p17 3+
102 undetected positive
6 HIV-2: sgp36 3+, sgp105 4+ HIV-1: sgp120 2+, gp41 3+, p31 2+, p24 4+,
p17 3+
nd nd nd
7 HIV-2: sgp36 2+, sgp105 2+ HIV-1: sgp120 3+, gp41 3+, p31 3+, p24 3+,
p17 2+
4039 nd nd
8 HIV-2: sgp36 3+, sgp105 3+ HIV-1: sgp120 2+, gp41 2+, p31 2+, p24 3+,
p17 0
nd nd nd
9 HIV-2: sgp36 1+, sgp105 1+ HIV-1: sgp120 2+, gp41 3+, p31 2+, p24 3+,
p17 2+
4618 nd nd
and, not done.
doi:10.1371/journal.pone.0157690.t001
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than HIV-1 RNA [12, 13], the diagnostic sensitivity of NAT for HIV-2 RNA is low and a nega-
tive test result does not exclude HIV-2 infection. Given the low sensitivity of standard PCR for
detection of proviral HIV-2 DNA, a Mega-PCR was developed and successfully applied in the
past [5]. However, in most cases presented here, Mega-PCR was not performed and the diag-
nosis of HIV-2 was based on Inno-Lia alone.
We conclude that a significant number of HIV-1 and HIV-2 dual infections would be
underreported when following the alternative strategy of HIV diagnosis as proposed by CDC.
Application of an ADI early at HIV diagnosis is highly recommended to identify HIV-2 co-
infections and guidance of appropriate therapy irrespective of epidemic data.
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